BACKGROUND: The aim of this study was to investigate the expression of ubiquitin-specific peptidase 9, X-linked (USP9X) in non-small cell lung cancer (NSCLC) patients and to evaluate the relevance of USP9X expression to tumor prognosis. METHODS: Ninety-five patients who underwent surgical resection for clinical stage I-IIIA NSCLC between July 2008 and July 2011 were included in this study. Immunohistochemical analysis of USP9X expression was performed on 95 NSCLC tissues and 32 adjacent normal lung parenchymal tissues from these patients. The Chi-squared test was used to compare the clinicopathological characteristics between different groups. Kaplan-Meier analysis and a Cox regression model were used to determine the independent prognostic factors. A P value <0.05 was considered to be significant. RESULTS: The expression of USP9X was found to be significantly higher in NSCLC tissue (44.2%) than in adjacent normal lung parenchymal tissue (6.3%) (P<0.001). High USP9X expression was significantly associated with positive lymph node metastasis (P<0.001), clinical stage (P<0.001) and a reduced overall survival rate (P=0.001) in patients with NSCLC. Based on the multivariate analysis, the elevated expression of the USP9X protein was a significant predictor of poor prognosis for NSCLC patients (HR =2.244, P=0.028). CONCLUSIONS: The current study demonstrated that the expression of USP9X in NSCLC tissue was significantly higher than that in normal lung tissue and that this elevated expression level of USP9X was associated with poor prognosis among NSCLC patients, suggesting that USP9X might serve as a prognostic biomarker for NSCLC.
BACKGROUND: The aim of this study was to investigate the expression of ubiquitin-specific peptidase 9, X-linked (USP9X) in non-small cell lung cancer (NSCLC) patients and to evaluate the relevance of USP9X expression to tumor prognosis. METHODS: Ninety-five patients who underwent surgical resection for clinical stage I-IIIA NSCLC between July 2008 and July 2011 were included in this study. Immunohistochemical analysis of USP9X expression was performed on 95 NSCLC tissues and 32 adjacent normal lung parenchymal tissues from these patients. The Chi-squared test was used to compare the clinicopathological characteristics between different groups. Kaplan-Meier analysis and a Cox regression model were used to determine the independent prognostic factors. A P value <0.05 was considered to be significant. RESULTS: The expression of USP9X was found to be significantly higher in NSCLC tissue (44.2%) than in adjacent normal lung parenchymal tissue (6.3%) (P<0.001). High USP9X expression was significantly associated with positive lymph node metastasis (P<0.001), clinical stage (P<0.001) and a reduced overall survival rate (P=0.001) in patients with NSCLC. Based on the multivariate analysis, the elevated expression of the USP9X protein was a significant predictor of poor prognosis for NSCLCpatients (HR =2.244, P=0.028). CONCLUSIONS: The current study demonstrated that the expression of USP9X in NSCLC tissue was significantly higher than that in normal lung tissue and that this elevated expression level of USP9X was associated with poor prognosis among NSCLCpatients, suggesting that USP9X might serve as a prognostic biomarker for NSCLC.
Authors: Rania Mouchantaf; Bilal A Azakir; Peter S McPherson; Susan M Millard; Stephen A Wood; Annie Angers Journal: J Biol Chem Date: 2006-10-12 Impact factor: 5.157
Authors: Chiara Luise; Maria Capra; Maddalena Donzelli; Giovanni Mazzarol; Maria Giovanna Jodice; Paolo Nuciforo; Giuseppe Viale; Pier Paolo Di Fiore; Stefano Confalonieri Journal: PLoS One Date: 2011-01-25 Impact factor: 3.240
Authors: Pedro A Pérez-Mancera; Alistair G Rust; Louise van der Weyden; Glen Kristiansen; Allen Li; Aaron L Sarver; Kevin A T Silverstein; Robert Grützmann; Daniela Aust; Petra Rümmele; Thomas Knösel; Colin Herd; Derek L Stemple; Ross Kettleborough; Jacqueline A Brosnan; Ang Li; Richard Morgan; Spencer Knight; Jun Yu; Shane Stegeman; Lara S Collier; Jelle J ten Hoeve; Jeroen de Ridder; Alison P Klein; Michael Goggins; Ralph H Hruban; David K Chang; Andrew V Biankin; Sean M Grimmond; Lodewyk F A Wessels; Stephen A Wood; Christine A Iacobuzio-Donahue; Christian Pilarsky; David A Largaespada; David J Adams; David A Tuveson Journal: Nature Date: 2012-04-29 Impact factor: 49.962
Authors: Yong Wu; Xiaoting Yu; Xianghua Yi; Ke Wu; Sami Dwabe; Mohammad Atefi; Yahya Elshimali; Kevin T Kemp; Kruttika Bhat; Jesse Haro; Marianna Sarkissyan; Jaydutt V Vadgama Journal: Cancer Res Date: 2017-01-23 Impact factor: 13.312
Authors: Aleksandra Toloczko; Fusheng Guo; Hiu-Fung Yuen; Qing Wen; Stephen A Wood; Yan Shan Ong; Pei Yi Chan; Asfa Alli Shaik; Jayantha Gunaratne; Mark J Dunne; Wanjin Hong; Siew Wee Chan Journal: Cancer Res Date: 2017-07-18 Impact factor: 12.701